# CHEMISTRY
## A European Journal

## Accepted Article

This manuscript has been accepted after peer review and appears as an Accepted Article online prior to editing, proofing, and formal publication of the final Version of Record (VoR). This work is currently citable by using the Digital Object Identifier (DOI) given below. The VoR will be published online in Early View as soon as possible and may be different to this Accepted Article as a result of editing. Readers should obtain the VoR from the journal website shown below when it is published to ensure accuracy of information. The authors are responsible for the content of this Accepted Article.

WILEY-VCH

# Biocatalytic production of psilocybin and derivatives in tryptophan synthase-enhanced reactions

Felix Blei, Florian Baldeweg, Janis Fricke, and Dirk Hoffmeister*[a]

**Abstract:** Psilocybin (4-phosphoryloxy-*N,N*-dimethyltryptamine) is the main alkaloid of the fungal genus *Psilocybe*, the so-called "magic mushrooms". The pharmaceutical interest in this psychotropic natural product as a future medication to treat depression and anxiety is strongly re-emerging. Here, we present an enhanced enzymatic route of psilocybin production by adding TrpB, the tryptophan synthase of the mushroom *Psilocybe cubensis*, to the reaction. We capitalized on its substrate flexibility and show psilocybin formation from 4-hydroxyindole and L-serine, which are less cost-intensive substrates, compared to the previous method. Further, we show enzymatic production of 7-phosphoryloxytryptamine (isonorbaeocystin), a non-natural congener of the *Psilocybe* alkaloid norbaeocystin (4-phosphoryloxytryptamine), and of serotonin (5-hydroxytryptamine) via the same *in vitro* approach.

Among the most prominent natural products is the L-tryptophan (**1**)-derived alkaloid psilocybin (4-phosphoryloxy-*N,N*-dimethyltryptamine, **2**, Scheme 1).[1] This major metabolite of *Psilocybe* carpophores - colloquially dubbed magic mushrooms - rapidly dephosphorylates upon ingestion to yield psilocin (**3**) which acts as the actual hallucinogen by agonistically binding to primarily the human 5HT$_{2A}$-receptor.[2] Importantly, recent clinical studies plausibly underscore the potential pharmaceutical value of **2** in the treatment of nicotine addiction, anxiety with terminal-stage cancer patients, and depression.[3]

For access to **2** and **3**, various synthetic approaches have been established.[4] Recently, a biotechnological three-enzyme route beginning from 4-hydroxy-L-tryptophan (**4**, Scheme 1) to **2** has been reported. This route utilizes the *Psilocybe cubensis* enzymes PsiD, PsiK, and PsiM, which provide decarboxylase, kinase, and methyltransferase activity, respectively.[5] We sought to enhance this enzymatic procedure by enzymatically producing **4** *in situ* via tryptophan synthase (E.C. 4.2.1.20), thus feeding lower-priced precursors to the process. The α-subunits of α$_2$β$_2$-heterotetrameric bacterial tryptophan synthases catalyze the first half reaction (Figure 1), that is, the retro aldol-type cleavage of 1-(indole-3-yl)glycerol phosphate that releases D-glyceraldehyde 3-phosphate and provides the indole (**5**, Scheme1) as substrate for the subsequent second half reaction. It is catalyzed by the β-subunit and includes a pyridoxal phosphate (PLP)-dependent condensation of **5** and L-serine (**6**, Figure 1) into **1**.[6] Wild type or engineered prokaryotic tryptophan synthases of *Salmonella*

*enterica* or *Pyrococcus furiosus* proved valuable in procuring β-methyl- or L-halotryptophans, respectively, via enzymatic conversion of substituted **5** and **6** (or L-threonine) by the β-subunit.[7] A recent study showed production of 4-halogenated or 4-nitro tryptophan by engineered TrpB variants.[8] Otherwise, tryptophan synthases generally turned out little tolerant towards 4-substituted indoles. Further, hydroxy-substituted indoles, which are relevant for our purposes, had not been included in prior studies.



L-tryptophan (**1**): R$^1$=R$^2$=R$^3$=R$^4$=H
4-hydroxy-L-tryptophan (**4**): R$^1$=OH, R$^2$=R$^3$=R$^4$=H
7-hydroxy-L-tryptophan (**14**): R$^1$=R$^2$=R$^3$=H, R$^4$=OH
5-hydroxy-L-tryptophan (**15**): R$^1$=R$^3$=R$^4$=H, R$^2$=OH

psilocybin (**2**): R$^1$=O-PO$_3$H$_2$, R$^2$=H, R$^3$=R$^4$=CH$_3$
psilocin (**3**): R$^1$=OH, R$^2$=H, R$^3$=R$^4$=CH$_3$
isonorbaeocystin (**10**): R$^1$=R$^3$=R$^4$=H, R$^2$=O-PO$_3$H$_2$
norbaeocystin (**11**): R$^1$=O-PO$_3$H$_2$, R$^2$=R$^3$=R$^4$=H
baeocystin (**16**): R$^1$=O-PO$_3$H$_2$, R$^2$=R$^3$=H, R$^4$=CH$_3$

indole (**5**): R$^1$=R$^2$=R$^3$=R$^4$=H
4-hydroxyindole (**7**): R$^1$=OH, R$^2$=R$^3$=R$^4$=H
7-hydroxyindole (**8**): R$^1$=R$^2$=R$^3$=H, R$^4$=OH
5-hydroxyindole (**9**): R$^1$=R$^3$=R$^4$=H, R$^2$=OH
6-hydroxyindole (**13**): R$^1$=R$^2$=R$^4$=H, R$^3$=OH

serotonin (**12**)

**Scheme 1.** Structures of *Psilocybe* tryptophan synthase substrates and products, and products of the *in vitro* reconstituted indole alkaloid synthesis pathway.

We recombinantly produced *P. cubensis* L-tryptophan synthase (TrpB). Here, we report on integrating it into a one-pot procedure to synthesize **2** from **6** and 4-hydroxyindole (**7**), i.e., two inexpensive compounds, in four enzymatic steps, using enzymes of the same fungus. Choosing 7-hydroxyindole (**8**) and 5-hydroxyindole (**9**), we further describe an enzymatic synthesis for isonorbaeocystin (7-phosphoryloxytryptamine, **10**), *i.e.*, a non-natural isomer of the psilocybin-family alkaloid norbaeocystin (**11**, Scheme 1). We also show TrpB/PsiD-catalyzed synthesis of serotonin (**12**) in two enzymatic steps.

Typically, fungal tryptophan synthases are homodimers. Each monomer is bifunctional, includes an α- and a β-domain, and shows a mass of about 75 kDa.[9] Using known fungal TrpB sequences as query,[10] we identified a 2648 bp candidate gene in the genome of *P. cubensis*[5] that was disrupted by ten introns, according to an *in silico* analysis with Augustus software.[11]

[a]    F. Blei, F. Baldeweg, J. Fricke, Prof. Dr. D. Hoffmeister
       Department Pharmaceutical Microbiology at the Hans-Knöll-Institute
       Friedrich-Schiller-Universität
       Beutenbergstrasse 11a, 07745 Jena (Germany)
       E-mail: dirk.hoffmeister@leibniz-hki.de

       Supporting information for this article is given via a link at the end of the document

**Figure 1.** The tryptophan synthase reaction. Indole (**5**) formation is catalyzed by the α-subunit (TrpB(α)), L-tryptophan (**1**) production is catalyzed by the β-subunit (TrpB(β)).

The 2103 bp coding sequence encodes a 700 aa TrpB monomer (calculated molecular mass 75.5 kDa, calculated pI 5.9). The protein was most similar (85% identical aa) to predicted proteins of the mushrooms *Hebeloma cylindrosporum* (accession # KIM48772.1) and of *Galerina marginata* (KDR73575.1). The *trpB* cDNA was inserted into expression vector pET28a to create plasmid pFB14. It was used to transform *E. coli* KRX to produce TrpB as *N*-terminally tagged polyhistidine fusion protein (Figure S1).



**Figure 2.** Product formation by *Psilocybe cubensis* TrpB. Chromatograms were extracted at λ=280 nm, HR-ESIMS spectra of the compounds given in parentheses were recorded in positive mode, experimentally determined masses are indicated in the spectra. The calculated mass of **4**, **14**, and **15** is *m/z* 221.0926 ([*M*+H]⁺), the calculated mass of **1** is *m/z* 205.0972. Top trace: overlayed separate chromatograms of authentic standards. Trace a: negative control with heat-treated TrpB and **5**. Trace b: reaction with **6** and **5**. Trace c: reaction with **6** and **7**. Trace d: reaction with **6** and **9**. Trace e: reaction with **6** and **8**. Trace f: reaction with **6** and **13**.

Optimum turnover took place at pH=8.0 and at 30°C. TrpB followed Michaelis-Menten kinetics and showed $K_m$ values of 40

μM and 16 μM for **5** and **7**, respectively, and 2.9 mM for **6** (Figure S2). The values for **5** and **6** are comparable with prior data.[7e,9] Gel permeation chromatography confirmed the dimeric state of active TrpB (Figure S3). The TrpB substrate specificity was assessed using **7**, **8**, **9**, or 6-hydroxyindole (**13**, Figure 2). Indoles **7**, **8**, and **9**, were converted to 4-, 7-, and 5-hydroxy-L-tryptophan (compounds **4**, **14**, and **15**, respectively, at $t_R$=10.2, 9.8, and 7.9 min), as determined by LC-MS (Figure 2, found masses *m/z* 221.0920, 221.0930, and 221.0927 [*M*+H]⁺, respectively, calculated for $C_{11}H_{13}N_2O_3$: 221.0926). Product formation was not detected in the reaction with **13**, a signal with the expected mass and UV/Vis spectrum was not found.



**Figure 3.** *In vitro* syntheses leading to serotonin (**12**), psilocybin (**2**), or isonorbaeocystin (**10**). The reactions included *Psilocybe cubensis* enzymes TrpB, PsiD, PsiK, and PsiM.

Next, we extended the described PsiD/PsiK/PsiM-dependent **2** *in vitro* synthesis by adding TrpB and PLP to this multi-enzyme assay. Substrates **6** and **7** were initially present at 3 mM, and the reaction proceeded for 4 h. LC-MS analysis unequivocally proved **2** production, along with its immediate natural precursors baeocystin (**16**) and **11** (Figure 3, Figure 4).

The substrate tolerance of the Psi enzymes outside the **2** biosynthesis pathway has not been investigated in greater detail. Considering that **15** was a TrpB product, we re-ran the four-enzyme reaction, this time adding 3 mM **6** and **9** as respective substrates. LC-MS-analysis demonstrated that a product had

formed ($t_R$=7.4 min) whose mass suggested the loss of $CO_2$ ($m/z$ 177.1022 [$M$+H]$^+$) hence implying **15** formation and subsequent quantitative PsiD-catalyzed decarboxylation into **12**. This was confirmed by comparison with an authentic **12** standard. This finding further suggested that PsiD tolerates well the 5-hydroxy substitution, which confirmed a previous report.[12] The results also showed that 5-hydroxylated indoles do not serve as substrates for the kinase PsiK, as no second, *i.e.*, phosphorylated product was detectable. Assays run only with TrpB and PsiD resulted in identical chromatograms (Figure 4).

We repeated the four-enzyme reaction with **6** and **8**. LC-MS analysis indicated formation of a product whose UV/Vis spectrum and mass ($m/z$ 257.0682 [$M$+H]$^+$) were equal to that of **11** (Figure 4, $t_R$=2.9 min), but which differed in its retention time ($t_R$=4.2 min), thus pointing to an isomeric product. Assuming that PsiD tolerates the 7-hydroxy group and that PsiK accepts it as phosphate acceptor substrate, we hypothesized that this product was identical to 7-phosphoryloxytryptamine (**10**, Scheme 1). We chromatographically purified this compound from an upscaled assay, which yielded 2.36 mg of pure substance.



**Figure 4.** LC-MS analysis of product formation in multi-enzyme assays. Chromatograms were extracted at λ=280 nm, HR-ESIMS spectra were recorded in positive mode, experimentally determined masses are indicated in the spectra. The calculated mass ([$M$+H]$^+$) of **2** is $m/z$ 285.0999, of **10** and **11**: $m/z$ 257.0686, of **12**: $m/z$ 177.1022. Top trace: overlayed separate chromatograms of standards. Trace a: Reaction with TrpB, PsiD, PsiK, and PsiM and substrates **6** and **7**. The signal at $t_R$=4.8 min is due to *S*-adenosyl-ʟ-homocysteine. Trace b: negative control. Trace c: Reaction with TrpB and PsiD with substrates **6** and **9** (trace d: negative control). Trace e: Reaction with TrpB, PsiD, PsiK, and PsiM with substrates **6** and **8** (trace f: negative control). Signals at $t_R$=9.7 and 9.6 min in traces a and e, respectively, represent intermediates 4- and 7-hydroxytryptamine, as identified by their UV/Vis spectra and by mass spectrometry ($m/z$ 177.1 [$M$+H]$^+$).

1D and 2D NMR spectra (Table 1, Figure S4-S9) were recorded and compared to NMR data of **2** (Table 2, Figure S4 and S10-S14). In **10**, the bridgehead carbon C-3a was identified by HMBC correlations with H-1 and H-2, while C-7a was correlated to H-2. The HMBC correlation between carbons C-3a and C-7 with the H-5 triplet established the position of the phosphoryloxy group at C-7 (Figure S9). The signal at δ=7.31 ppm (H-4)

showed HMBC correlations with C-3, C-6, and C-7a, thus providing final evidence for the structure of compound **10**, for which we propose the name isonorbaeocystin. Methylation of **10** by PsiM in detectable amounts was not observed.

**Table 1.** $^1$H (600 MHz) and $^{13}$C (150 MHz) NMR data for **10** in DMSO-$d_6$.

| Pos. | $\delta_H$ (mult. $J$ [Hz]) | $\delta_C$ | HMBC | COSY |
|---|---|---|---|---|
| 1 | 10.97 (s, 1H) | - | 3, 3a | 2 |
| 2 | 7.20 (d, 2.0, 1H) | 123.9 | 3, 3a, 7a | 1 |
| 3 | - | 109.9 | - | - |
| 3a | - | 129.5 | - | - |
| 4 | 7.31 (d, 7.86, 1H) | 113.8 | 3, 6, 7a | 5 |
| 5 | 6.95 (t, 7.77, 1H) | 118.7 | 3a, 7 | 4, 6 |
| 6 | 7.02 (d, 7.68, 1H) | 111.3 | 4, 7a, 7 | 5 |
| 7 | - | 137.8 | - | - |
| 7a | - | 128.2 | - | - |
| 1' | 3.07 (m, 2H) | 39.3[a] | 3 | 2', NH$_2$ |
| 2' | 2.97 (t, 7.62, 2H) | 23.2 | 1', 2, 3, 3a | 1' |
| NH$_2$ | 7.75 (s, 2H) | - | - | 1' |

[a] value derived from 2D $^1$H-$^{13}$C correlation spectrum (HMBC).

**Table 2.** $^1$H (600 MHz) and $^{13}$C (150 MHz) NMR data for **2** in DMSO-$d_6$.

| Pos. | $\delta_H$ (mult. $J$ [Hz]) | $\delta_C$ | HMBC | COSY |
|---|---|---|---|---|
| 1 | 11.09 (s, 1H) | - | 3, 3a | 2 |
| 2 | 7.18 (d, 1.98, 1H) | 123.7 | 3, 3a, 7a | 1 |
| 3 | - | 108.2 | - | - |
| 3a | - | 118.7 | - | - |
| 4 | - | 145.2 | - | - |
| 5 | 7.12 (d, 7.98, 1H) | 107.6 | 3a, 7 | 6 |
| 6 | 6.99 (t, 7.74, 1H) | 121.5 | 7a, 4 | 5, 7 |
| 7 | 6.93 (d, 7.89, 1H) | 108.7 | 3a, 4, 5 | 6 |
| 7a | - | 138.6 | - | - |
| 1' | 3.32 (m, 2H) | 58.1 | 2', 3, N(CH$_3$)$_2$ | 2' |
| 2' | 3.18 (m, 2H) | 21.2 | 1', 2, 3, 3a | 1' |
| N(CH$_3$)$_2$ | 2.82 (s, 6H) | 42.3 | 1', 2' | - |

Therefore, we conclude that PsiM, the methyltransferase of the **2** pathway, cannot tolerate a 7-phosphoryloxy-substituted compound as acceptor substrate. This finding underscores the previously noted specificity of PsiM, which prevents *N*,*N*-dimethyltryptamine and **3** formation as intermediates in the **2** pathway.[5]

Contrasting the use of the *trpB* gene in fungal genetics as a standard selection marker in **1**-auxotrophic hosts, very few fungal tryptophan synthases were investigated biochemically.[9a,13] *P. cubensis* TrpB is the first biochemically characterized tryptophan synthase of the basidiomycetes, which represent a phylum of more than 30,000 species. The intrinsic tolerance of TrpB to substituted indoles allowed for its integration into a biocatalytic process that produces **2** congeners, including **10** and **12**, and that translates into a facile and more cost-effective enzymatic synthesis of **2**. The value of the substrate **4**, used in the previous procedure, is approximately US$ 180/mmol, whereas the combined sales price for 1 mmol (each) of **6** and **7** as starting material in our refined process is about US$ 2.

Directed *in vitro* evolution and structure-based engineering of genes encoding biosynthesis enzymes proved instrumental to optimize catalytic activity, introduce new activities, relax specificities, to create libraries of natural product derivatives.[14] Thus, future work on enzyme engineering, in particular on the strictly specific methyltransferase PsiM, is warranted to access a larger structural diversity of **2** derivatives using only a small set of enzymes.

## Experimental Section

**Enzymatic reactions**: All enzymatic *in vitro* reactions were carried out in triplicate. The enzyme concentration was 200 nM. In the case of multi-enzyme assays, each enzyme was present at this concentration. The reactions were stopped after the indicated incubation times by freezing and lyophilization. Subsequently, the residue was dissolved in methanol (MeOH), centrifuged for 10 min at 20,000 × g, and the supernatant was collected. The solvent was removed under reduced pressure, and the residue dissolved in $H_2O$:acetonitrile (9:1, v/v), filtered, and used for chromatography (see below). The *in vitro* characterization of TrpB was performed in a volume of 100 μL and 50 mM Tris-HCl buffer, pH=8.0 for 5 min at 30°C (varied between 16-42°C to determine the temperature optimum, and between pH=6.0 through 9.5 for the pH optimum). The substrates (**6**, and the respective indole substrate **5**, **7**, **8**, **9**, or **13**) were added at (each) 3 mM, the PLP concentration was 1 μM. Multi-enzyme reactions including TrpB, PsiD, PsiK, and PsiM were set up in a volume of 500 μL in 50 mM Tris-HCl buffer, pH=8.0, and proceeded for 4 h at 25°C. The reactions yielding **2**, **10**, or **12** included **6** and indole substrates **7**, **8**, or **9** (3 mM final concentration each) as well as SAM, ATP, and $MgCl_2$ (6 mM each), the PLP concentration was 1 μM. Initially, all four enzymes were added. For subsequent assays yielding **12**, PsiK, PsiM, ATP, and SAM was omitted. The yield of **2** (20.7%) was determined by calculating the area under the curve of its chromatographic signal and compared to a standard curve, recorded with authentic compound.

**Chemical analysis:** LC-MS experiments were performed on an Agilent 1260 HPLC system equipped with a $C_{18}$ column (Zorbax Eclipse XDB, 150 × 4.6 mm, 5 μm) and coupled to a 6130 Single Quadrupole mass detector, high-resolution mass spectrometry was performed on a Thermo Accela liquid chromatograph, following described parameters.[5] The 1D and 2D NMR spectra of **10** and **2** were recorded at 300 K on a Bruker Avance III spectrometer at 600 MHz for $^1$H and at 150 MHz for $^{13}$C spectra. DMSO-$d_6$ was used as solvent and internal standard. The solvent signals were referenced to $\delta_H$ 2.50 ppm and $\delta_C$ 39.5 ppm. Chemicals and solvents were purchased from Deutero, Key Organics,

Sigma-Aldrich, Roth, TCI, and VWR. Alkaloids **2**, **11**, and **16** were purified from *P. cubensis* carpophores.

Detailed experimental procedures for microbiological, and genetic methods, as well as for purification of enzymes and compound **10** are described in the Supporting Information.

[1]     a) A. Hofmann, R. Heim, A. Brack, H. Kobel, A. Frey, H. Ott, T. Petrzilka, F. Troxler, *Helv. Chim. Acta* **1959**, *42*, 1557-1572; b) A.Y. Leung, A.H. Smith, A.G. Paul, *J. Pharm. Sci.* **1965**, *54*, 1576-1579.

[2]     a) D.E. Nichols, *Pharmacol. Ther.* **2004**, *101*, 131-181; b) F. Hasler, U. Grimberg, M.A. Benz, T. Huber, F.X. Vollenweider, *Psychopharmacol.* **2004**, *172*, 145-156.

[3]     a) C.S. Grob, A.L. Danforth, G.S. Chopra, M. Hagerty, C.R. McKay, A.L. Halberstadt, G.R. Greer, *Arch. Gen. Psychiat.* **2011**, *68*, 71-78; b) M.W. Johnson, A. Garcia-Romeu, M.P. Cosimano, R.R. Griffiths, *J. Psychopharmacol.* **2014**, *28*, 983-992; c) A. Mahapatra, R. Gupta, *Ther. Adv. Psychopharmacol.* **2017**, *7*, 54-56.

[4]     a) A. Hofmann, A. Frey, H. Ott, T. Petrzilka, F. Troxler, *Experientia* **1958**, *15*, 397-399; b) F. Troxler, F. Seemann, A. Hofmann, *Helv. Chim. Acta* **1959**, *42*, 2073-2103; c) S. Ametamey, F. X. Vollenweider, J. Patt, D. Bourquin, F. Hasler, H.-F. Beer, P. A. Schubiger, *J. Label. Compd. Radiopharm.* **1998**, *41*, 585-594; d) F. Yamada, M. Tamura, M. Somei, *Heterocycles* **1998**, *49*, 451; e) H. Sakagami, K. Ogasawara, *Heterocycles* **1999**, *51*, 1131-1135; f) D.E. Nichols, S. Frescas, *Synthesis* **1999**, 935-938; g) O. Shirota, W. Hakamata, Y. Goda, *J. Nat. Prod.* **2003**, *66*, 885-887; h) N. Gathergood, P.J. Scammells, *Org. Lett.* **2003**, *5*, 921-923.

[5]     J. Fricke, F. Blei, D. Hoffmeister, *Angew. Chem. Intl. Ed.* **2017**, *56*, 12352-12355.

[6]     a) E.W. Miles, H. Kawasaki, S.A. Ahmed, H. Morita, H. Morita, S. Nagata, *J. Biol. Chem.* **1989**, *264*, 6280-6287; b) M.F. Dunn, D. Niks, H. Ngo, T.R. Barends, I. Schlichting, *Trends Biochem. Sci.* **2008**, *33*, 254-264.

[7]     a) R.J. Goss, P.L. Newill, *Chem. Commun.* **2006**, *47*, 4924-4925; b) D.R. Smith, T. Willemse, D.S. Gkotsi, W. Schepens, B.U. Maes, S. Ballet, R.J. Goss, *Org. Lett.* **2014**, *16*, 2622-2625; c) D. Francis, M. Winn, J. Latham, M.F. Greaney, J. Micklefield, *ChemBioChem* **2017**, *18*, 382-386; d) M. Herger, P. van Roye, D.K. Romney, S. Brinkmann-Chen, A.R. Buller, F.H. Arnold, *J. Am. Chem. Soc.* **2016**, *138*, 8388-8391; e) A.R. Buller, S. Brinkmann-Chen, D.K. Romney, M. Herger, J. Murciano-Calles, F.H. Arnold, *Proc. Natl. Acad. Sci. USA* **2015**, 112, 14599-14604.

[8]     D.K. Romney, J. Murciano-Calles, J.E. Wehrmüller, F.H. Arnold, *J. Am. Chem. Soc.* **2017**, *139*, 10769-10776.

[9]     a) W.H. Matchett, J.A. DeMoss, *J. Biol. Chem.* **1975**, *250*, 2941-2946; b) C.J. Bailey, P.D. Turner, *Biochem. J.* **1983**, *209*, 151-157.

WILEY-VCH

[10] a) C. Skrzynia, D.M. Binninger, J.A. Alspaugh, P.J. Pukkila, *Gene* **1989**, *81*, 73-82; b) S.E. Eckert, E. Kübler, B. Hoffmann, G.H. Braus, *Mol. Gen. Genet.* **2000**, *263*, 867-876.

[11] M. Stanke, R. Steinkamp, S. Waack, B. Morgenstern, *Nucleic Acids Res.* **2004**, *32*, W309-312.

[12] H.T. Reynolds, V. Vijayakumar, E. Gluck-Thaler, H.B. Korotkin, P.B. Matheny, J.C. Slot, *Evol. Lett.* (doi: 10.1002/evl3.42).

[13] a) D.H. Wolf, M. Hoffmann, *Eur. J. Biochem.* **1974**, *45*, 269-276.

[14] C.A. Denard, H. Ren, H. Zhao, *Curr. Opin. Chem. Biol.* **2015**, *25*, 55-64; b) G. Williams, R.W. Gantt, J.S. Thorson, *Curr. Opin. Chem. Biol.* **2008**, *12*, 556-564.

## COMMUNICATION

WILEY-VCH

## COMMUNICATION

**Extended magic** - The tryptophan synthase TrpB of the "magic" mushroom *Psilocybe cubensis* was used to extend the *in vitro* three-enzyme route towards psilocybin. We show formation of this drug candidate from L-serine and 4-hydroxyindole. When 5- or 7-hydroxyindole was added, serotonin or the non-natural psilocybin congener isonorbaeocystin were formed.

*Felix Blei, Florian Baldeweg, Janis Fricke, and Dirk Hoffmeister\**

***Page No. – Page No.***

**Biocatalytic production of psilocybin and derivatives in tryptophan synthase-enhanced reactions**